摘要
目的:探讨应用阿糖腺苷和更昔洛韦治疗病毒性肺炎的疗效、不良反应及成本-效果比差异。方法采用回顾性分析,选择2012年1月~2014年1月病毒性肺炎患儿94例,将以上患者随机分为两组,阿糖腺苷组和更昔洛韦组。确定两组患者成本,分析两组患者成本效果。结果两组患者总有效率比较,差异无统计学意义(﹥0.05);获得1个单位效果情况下,更昔洛韦组所用成本小于阿糖腺苷组,差异有统计学意义(P<0.05)。结论更昔洛韦组静滴方案临床效果显著且成本较小。
Objective To investigate the cost-ef ectiveness of two dif erent treatments for the viral pneumonia with ganciclovir or vidarabine.Methods Chose 94 patients with viral pneumonia from January 2012 to January 2014,and divided them into two groups,vidarabine group and ganciclovir group.Results The total ef ective rates in two groups were not dif erent(﹥0.05);after 1 unit of ef ect,the cost in the ganciclovir group was smal er than that in the vidarabine group.Conclusion The clinical ef ect of ganciclovir is remarkable,and the cost is smal.
作者
谢纲
刘雅泓
邓小艳
张灿
XIE Gang;LIU Ya-hong;DENG Xiao-yan;ZHANG Can(Maternal and Child Health Hospital of Xiangtan City,Xiangtan 411100,Hunan,China)
